Q4 EPS Estimate for Pacira BioSciences Boosted by Analyst

Pacira BioSciences, Inc. (NASDAQ:PCRX) – Analysts at Zacks Research increased their Q4 2026 earnings per share estimates for Pacira BioSciences in a report issued on Tuesday, February 11th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $0.83 per share for the quarter, up from their previous estimate of $0.79. The consensus estimate for Pacira BioSciences’ current full-year earnings is $2.40 per share.

A number of other equities research analysts have also recently commented on PCRX. Truist Financial raised shares of Pacira BioSciences from a “sell” rating to a “hold” rating and increased their price objective for the company from $8.00 to $25.00 in a research note on Thursday, January 30th. HC Wainwright reiterated a “buy” rating and issued a $39.00 price target on shares of Pacira BioSciences in a research report on Wednesday, December 4th. Needham & Company LLC raised their price objective on shares of Pacira BioSciences from $22.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday, January 13th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $18.00 target price on shares of Pacira BioSciences in a research note on Tuesday, January 14th. Finally, Barclays dropped their price target on Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating for the company in a research report on Tuesday, November 12th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Pacira BioSciences currently has an average rating of “Hold” and an average price target of $22.78.

Pacira BioSciences Stock Down 2.2 %

Pacira BioSciences stock opened at $26.53 on Thursday. The firm has a market capitalization of $1.22 billion, a price-to-earnings ratio of -13.07 and a beta of 0.80. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. Pacira BioSciences has a fifty-two week low of $11.16 and a fifty-two week high of $31.67. The stock’s fifty day moving average is $21.72 and its two-hundred day moving average is $18.06.

Institutional Investors Weigh In On Pacira BioSciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. increased its position in Pacira BioSciences by 16.6% during the 4th quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company’s stock worth $68,000 after purchasing an additional 513 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in Pacira BioSciences by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,790 shares of the company’s stock worth $184,000 after buying an additional 918 shares during the period. Sterling Capital Management LLC increased its position in shares of Pacira BioSciences by 779.4% in the fourth quarter. Sterling Capital Management LLC now owns 1,363 shares of the company’s stock worth $26,000 after acquiring an additional 1,208 shares in the last quarter. Caitlin John LLC raised its stake in shares of Pacira BioSciences by 1,850.0% in the 4th quarter. Caitlin John LLC now owns 1,872 shares of the company’s stock valued at $35,000 after acquiring an additional 1,776 shares during the period. Finally, Teacher Retirement System of Texas raised its stake in shares of Pacira BioSciences by 17.4% in the 4th quarter. Teacher Retirement System of Texas now owns 13,708 shares of the company’s stock valued at $258,000 after acquiring an additional 2,034 shares during the period. 99.73% of the stock is currently owned by institutional investors and hedge funds.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.